Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donepezil + memantine (Dongkook Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Dongkook Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DKF-462 is a fixed-dose combination generic drug candidate developed by Dongkook Pharmaceutical for the treatment of moderate-to-severe Alzheimer's disease. It is a generic version of Hyundai Pharm's DM Duo (디엠듀오정), combining the acetylcholinesterase inhibitor donepezil hydrochloride (10 mg) and the NMDA receptor antagonist memantine hydrochloride (20 mg) into a single oral tablet. By combining these two complementary mechanisms of action, DKF-462 aims to improve cognitive function and daily living activities in patients with Alzheimer's disease while significantly reducing the pill burden and improving medication adherence. In June 2025, Dongkook Pharmaceutical received approval from the South Korean Ministry of Food and Drug Safety (MFDS) to conduct a bioequivalence study for DKF-462.
- Other names
- donepezil hydrochloride + memantine hydrochloridedonepezil/memantine
02
Targets
ButyrylcholinesteraseAcetylcholinesteraseNMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on donepezil + memantine (Dongkook Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donepezil + memantine (Dongkook Pharmaceutical).